Search

Your search keyword '"Pasini, A"' showing total 100 results
Start Over Author "Pasini, A" Journal digestive and liver disease
100 results on '"Pasini, A"'

1. OC.01.5: CHARACTERIZING INTRAEPITHELIAL LYMPHOCYTES IN POTENTIAL AND OVERT AUTOIMMUNE ATROPHIC GASTRITIS

Author

Soriano, S., primary, Lenti, M.V., additional, Aronico, N., additional, Bianchi, P.I., additional, Mengoli, C., additional, Miceli, E., additional, Gentile, A., additional, Di Terlizzi, F., additional, Santacroce, G., additional, Pasini, A., additional, Coppola, L., additional, Guerini, C., additional, De Lisi, G., additional, Vanoli, A., additional, De Silvestri, A., additional, Klersy, C., additional, Paulli, M., additional, Corazza, G.R., additional, and Di Sabatino, A., additional

Published
2024
Full Text
View/download PDF

14. P.02.16 SERUM SIALIC-ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN (SIGLEC)-7 AS A FIBROGENIC BIOMARKER IN CROHN'S DISEASE

Author

Dalila Mele, S. Soriano, C. Ubezio, A. Di Sabatino, Nicola Aronico, A. Pasini, G.R. Corazza, L.M. Bracchitta, Stefania Varchetta, Mario U. Mondelli, Sara Cococcia, and P. Giuffrida

Subjects
Crohn's disease, Hepatology, biology, business.industry, Gastroenterology, SIGLEC, Lectin, Sialic acid binding, medicine.disease, Immunology, medicine, biology.protein, Biomarker (medicine), Antibody, business
Published
2018
Full Text
View/download PDF

15. OC.06.6 CHARACTERISATION OF IMMUNE CELLS INFILTRATING THE CORPUS MUCOSA OF THE STOMACH IN AUTOIMMUNE ATROPHIC GASTRITIS

Author

A. Di Sabatino, Emanuela Miceli, A. Pasini, Flavio Caprioli, Sara Cococcia, Marco Vincenzo Lenti, G.R. Corazza, F. De Grazia, Federica Facciotti, and P. Giuffrida

Subjects
Pathology, medicine.medical_specialty, medicine.anatomical_structure, Immune system, Hepatology, business.industry, Atrophic gastritis, Stomach, Gastroenterology, medicine, business, medicine.disease
Published
2019
Full Text
View/download PDF

17. P.09.4 EVALUATION OF PROGNOSTIC FACTORS OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

Author

Bramuzzo, I., primary, Gerussi, A., additional, Maier, S., additional, Bianco, C., additional, Romanin, A., additional, Pasini, C. Laghi, additional, Barghini, V., additional, Scatà, L., additional, Donnini, D., additional, Uzzau, A., additional, Vit, A., additional, Sechi, L.A., additional, and Soardo, G., additional

Published
2018
Full Text
View/download PDF

20. P.01.9 INCREASED INTRAEPITHELIAL LYMPHOCYTE INFILTRATION OF THE STOMACH CORPUS IN AUTOIMMUNE ATROPHIC GASTRITIS

Author

A. Di Sabatino, G.R. Corazza, Alessandro Vanoli, A. Pasini, Francesca Capuano, Nicola Aronico, P. Giuffrida, L.M. Bracchitta, Emanuela Miceli, S. Soriano, Michele Martino, and Marco Vincenzo Lenti

Subjects
Pathology, medicine.medical_specialty, medicine.anatomical_structure, Hepatology, Atrophic gastritis, business.industry, Stomach, Gastroenterology, medicine, Intraepithelial lymphocyte, medicine.disease, business, Infiltration (medical)
Published
2018
Full Text
View/download PDF

21. P.09.4 EVALUATION OF PROGNOSTIC FACTORS OF OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

Author

A. Vit, V. Barghini, A. Gerussi, L.A. Sechi, D. Donnini, C. Laghi Pasini, S. Maier, A. Uzzau, A. Romanin, C. Bianco, Giorgio Soardo, I. Bramuzzo, and L. Scatà

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Gastroenterology, Overall survival, Medicine, In patient, Progression-free survival, business, medicine.disease
Published
2018
Full Text
View/download PDF

22. P.02.25 GLUCAGON-LIKE PEPTIDES (GLP) SECRETORY PROFILE IS RELATED TO BODY COMPOSITION AND INFLAMMATION INDEXES IN CROHN'S DISEASE AND METABOLIC SYNDROME PATIENTS

Author

Pietro Lucotti, C. Ubezio, P. Giuffrida, G.R. Corazza, Marco Vincenzo Lenti, Beatrice Valvo, A. Di Sabatino, Nicola Aronico, Elisabetta Lovati, A. Pasini, and Elisa Sprio

Subjects
medicine.medical_specialty, Crohn's disease, Hepatology, business.industry, Gastroenterology, Inflammation, medicine.disease, Endocrinology, Internal medicine, medicine, Glucagon-Like Peptides, Composition (visual arts), Metabolic syndrome, medicine.symptom, business
Published
2018
Full Text
View/download PDF

23. Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques

Author

Diego Miotto, R. De Caro, Annarosa Floreani, G.P. Feltrin, Veronica Macchi, R. Pasini, P. Marchesi, and Monica Zuliani

Subjects
Adult, Male, medicine.medical_specialty, Cholangitis, Sclerosing, Intrahepatic bile ducts, Sensitivity and Specificity, Primary sclerosing cholangitis, Biliary disease, Cholangiography, Humans, Medicine, Single-Blind Method, Hepatology, medicine.diagnostic_test, business.industry, Bile duct, Non invasive, Gastroenterology, Magnetic resonance imaging, medicine.disease, eye diseases, Bile Ducts, Intrahepatic, medicine.anatomical_structure, Maximum intensity projection, Female, Bile Ducts, sense organs, Radiology, Tomography, X-Ray Computed, business, human activities, Magnetic Resonance Angiography
Abstract

Background. Magnetic resonance cholangiography is a new technique which has already gained a role in primary sclerosing cholangitis. Computerised tomographic cholangiography is another non-invasive technique which has been used in assessing abnormal biliary tree, but has never been applied to evaluating primary sclerosing cholangitis. Aims. To evaluate the ability of both magnetic resonance cholangiography and computerised tomographic cholangiography to detect bile duct changes in primary sclerosing cholangitis. Patients and methods. Magnetic resonance cholangiography and computerised tomographic cholangiography were performed in 16 primary sclerosing cholangitis patients. The computerised tomographic cholangiography data set was transferred to a processing workstation to obtain tridimensional reconstructions. Magnetic resonance cholangiography and computerised tomographic cholangiography images were analysed blind by two radiologists to assess: primary sclerosing cholangitis involvement, quality of imaging and the radiologist’s certainty in determining the presence and location of the disease. Results. Mean imaging quality was significantly better with computerised tomographic cholangiography compared with magnetic resonance cholangiography. Primary sclerosing cholangitis was identified in 15 cases with computerised tomographic cholangiography and 10 with magnetic resonance cholangiography (P < 0.05). Sensitivity in diagnosing primary sclerosing cholangitis was 94% with computerised tomographic cholangiography versus 63% with magnetic resonance cholangiography. Intrahepatic location was found in 14 cases, definitely present in 10 cases with computerised tomographic cholangiography and five with magnetic resonance cholangiography. Extrahepatic location was found in 13 cases, definitely present in 11 cases with computerised tomographic cholangiography and four with magnetic resonance cholangiography (P < 0.05). Computerised tomographic cholangiography also offered dynamic information about biliary excretion. Conclusions. Computerised tomographic cholangiography enables more accurate detection and location of primary sclerosing cholangitis than magnetic resonance cholangiography. Since computerised tomographic cholangiography offers additional information about biliary excretion, it may be proposed as an integrative technique in the diagnosis and follow-up of patients with primary sclerosing cholangitis.

Published
2004
Full Text
View/download PDF

24. OC.02.2 HUMAN NEUTROPHIL ELASTASE CONTRIBUTES TO LOSS OF FUNCTION OF INFLIXIMAB IN ULCERATIVE COLITIS

Author

Renata Curciarello, Paolo Giuffrida, Gino Roberto Corazza, Alessandro Vanoli, Thomas T. MacDonald, Klaartje Kok, Massimo Pinzani, Paolo Biancheri, A. Pasini, A. Di Sabatino, and Giuseppe Mazza

Subjects
medicine.medical_specialty, Hepatology, Human neutrophil, business.industry, Elastase, Gastroenterology, medicine.disease, Ulcerative colitis, Infliximab, Internal medicine, medicine, business, Loss function, medicine.drug
Published
2016
Full Text
View/download PDF

28. P.06.22 MUCOSAL EXPRESSION OF THE RECEPTOR FOR THE ADVANCED GLYCATION END PRODUCTS (RAGE) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)

Author

A. Gallia, E. Betti, A. Rossi, G.R. Corazza, A. Pasini, Costanza Alvisi, R. Desio, G.C. Cangemi, V. Boccaccio, Mariaconcetta Russo, Venerina Imbesi, Rachele Ciccocioppo, and F. Racca

Subjects
Hepatology, business.industry, Glycation, Immunology, Gastroenterology, Medicine, In patient, business, medicine.disease, Receptor, Inflammatory bowel disease, RAGE (receptor)
Published
2012
Full Text
View/download PDF

33. P.03.4 SERUM HEPCIDIN IN INFLAMMATORY BOWEL DISEASES

Author

Di Sabatino, A., primary, Guerci, M., additional, Bergamaschi, G., additional, Albertini, R., additional, Costanzo, F., additional, Masotti, M., additional, Pasini, A., additional, Giuffrida, P., additional, Biancheri, P., additional, Campostrini, N., additional, Corbella, M., additional, Girelli, D., additional, and Corazza, G.R., additional

Published
2013
Full Text
View/download PDF

34. P.03.4 SERUM HEPCIDIN IN INFLAMMATORY BOWEL DISEASES

Author

Michela Corbella, Gaetano Bergamaschi, Natascia Campostrini, Filippo Costanzo, A. Di Sabatino, Marco Guerci, Michela Masotti, P. Giuffrida, G.R. Corazza, A. Pasini, Domenico Girelli, Riccardo Albertini, and Paolo Biancheri

Subjects
chemistry.chemical_classification, medicine.medical_specialty, Messenger RNA, Hepatology, biology, business.industry, Tissue transglutaminase, Gastroenterology, Inflammatory Bowel Diseases, Peptide, medicine.disease, digestive system, digestive system diseases, Endocrinology, chemistry, Hepcidin, Internal medicine, Gene expression, medicine, Colon tissue, biology.protein, Colitis, business
Abstract

20)-untreated) rats. 2) TNBS up-regulated mRNA expression of COX-2, TGF-β, TNF-α, HB-EGF and t-TG in colonic tissue. 3) both concentrations of Hp 2-20 significantly (p

Published
2013
Full Text
View/download PDF

35. P.05.7 ALTERED EXPRESSION OF TYPE-1 AND TYPE-2 CANNABINOID RECEPTORS IN COELIAC DISEASE

Author

Gino Roberto Corazza, Cinzia Rapino, Chiara Montana Montana, A. Pasini, Paolo Giuffrida, A. Di Sabatino, Natalia Battista, M. Maccarone, Cinzia Papadia, M. Di Tommaso, Paolo Biancheri, and Francesco Lanzarotto

Subjects
medicine.medical_specialty, Endocrinology, Cannabinoid receptor, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, medicine.disease, business, Coeliac disease
Published
2013
Full Text
View/download PDF

36. P.12.22 MARKED ACTIVATION OF MUCOSAL PRO-INFLAMMATORY IMMUNE RESPONSE IN DIVERTICULITIS BUT NOT IN DIVERTICULOSIS

Author

G.R. Corazza, Paolo Biancheri, P. Giuffrida, C. Salvatore, C. Ubezio, Alessandro Massari, A. Pasini, A. Di Sabatino, Thomas T. MacDonald, Klaartje Kok, and Marco Guerci

Subjects
medicine.medical_specialty, Immune system, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Diverticulitis, medicine.disease, business, Diverticulosis
Published
2013
Full Text
View/download PDF

37. P.05.15 IS ULCERATIVE COLITIS AN ATYPICAL T HELPER 2-MEDIATED DISEASE CHARACTERISED BY EXCESSIVE PRODUCTION OF INTERLEUKIN-13?

Author

Biancheri, P., primary, Ammoscato, F., additional, Di Sabatino, A., additional, Joe-Njoku, I., additional, Rovedatti, L., additional, Pasini, A., additional, Ubezio, C., additional, Guerci, M., additional, Giuffrida, P., additional, Quadrelli, A., additional, Macdonald, T.T., additional, and Corazza, G.R., additional

Published
2012
Full Text
View/download PDF

38. P.06.22 MUCOSAL EXPRESSION OF THE RECEPTOR FOR THE ADVANCED GLYCATION END PRODUCTS (RAGE) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)

Author

Ciccocioppo, R., primary, Boccaccio, V., additional, Russo, M.L., additional, Gallia, A., additional, Betti, E., additional, Imbesi, V., additional, Racca, F., additional, Cangemi, G., additional, Pasini, A., additional, Alvisi, C., additional, Desio, R., additional, Rossi, A., additional, and Corazza, G.R., additional

Published
2012
Full Text
View/download PDF

43. OC.03.4 EFFECT OF TUMOR NECROSIS FACTOR-ALPHA BLOCKADE ON MUCOSAL ADDRESSIN CELL-ADHESION MOLECULE-1 (MADCAM-1) EXPRESSION IN CROHN'S DISEASE

Author

A. Di Sabatino, Francesca Vidali, Silvio Danese, C. Salvatore, G.R. Corazza, Paolo Biancheri, Stefania Vetrano, C. Ubezio, Paolo Giuffrida, A. Pasini, and Alessandro Massari

Subjects
Crohn's disease, Hepatology, biology, Cell adhesion molecule, business.industry, Gastroenterology, medicine.disease, Blockade, Immunology, Addressin, biology.protein, medicine, Tumor necrosis factor alpha, business
Published
2012
Full Text
View/download PDF

44. P.05.15 IS ULCERATIVE COLITIS AN ATYPICAL T HELPER 2-MEDIATED DISEASE CHARACTERISED BY EXCESSIVE PRODUCTION OF INTERLEUKIN-13?

Author

Marco Guerci, A. Di Sabatino, I. Joe-Njoku, A. Pasini, G.R. Corazza, Laura Rovedatti, C. Ubezio, F. Ammoscato, Paolo Biancheri, Thomas T. MacDonald, A. Quadrelli, and Paolo Giuffrida

Subjects
medicine.medical_specialty, Hepatology, business.industry, Gastroenterology, Disease, medicine.disease, Ulcerative colitis, T helper 2, Refractory, Maintenance therapy, Internal medicine, Interleukin 13, Medicine, Electronic database, business, Adverse effect
Abstract

The aim of this study was to compare the outcomes of therapy with IFX and ADA in CD patients in daily clinical practice. Material and methods: All CD patients treated with anti TNF-alpha antibodies form July 1999 to September 2011 at “Casa Sollievo della Sofferenza” Hospital were enrolled. Demographical and clinical data were collected in an electronic database for the analysis. Results: A total of 188 patients (113 treated with IFX and 75 with ADA) were enrolled. The mean age at diagnosis was 29±12 (IFX) vs 34±14 (ADA) (p=0.003). The mean duration of disease was 8±6 years for both groups. Ileocolonic disease was significantly more frequent in IFX patients (45 vs 19 pts, p=0.03). Luminal disease (74 IFX vs 61 ADA, p=0.02), fistulizing disease (28 IFX vs 12 ADA, p=0.004), and extraintestinal manifestations (11 IFX vs 2 with ADA, p=0.07) were the indications for therapy. All patients treated with ADA vs 66 (58%) treated with IFX received a maintenance therapy; the mean duration of treatment was 12±10 for ADA vs 6±6 months for IFX (p=0.0003). The response rate was similar (76% IFX and 67% ADA; p=0.17). Five of 6 patients (83%) non-responder to ADA and 7 of 10 patients refractory to IFX responded to the alternative anti-TNF (p=ns). 107 patients were treated with immunosuppressants (76 with IFX and 31 with ADA; p=0.0005). The response rate did not improve with the combo therapy in both groups. 74 patients were active smokers (49 treated with IFX and 25 with ADA; p=0.1). The response rate was significantly lower in smokers treated with IFX (71.4% vs 92%, p=0.005). 15 (13%) patients treated with IFX and 10 (14%) treated with ADA had adverse events (AEs) (p=ns). No differences in AE rate between patients in mono or combo therapy were found. Conclusions: IFX and ADA showed similar efficacy and safety. Current smokers showed a significant lower response rate only in patients treated with IFX. Most patients refractory to an antiTNF may respond to the other. Prospective, randomized head to head studies comparing IFX to ADA are strongly desiderable.

Published
2012
Full Text
View/download PDF

45. P.63 INTERLEUKIN (IL)-17A BUT NOT IL-17E IS PROFIBROTIC IN CROHN'S DISEASE

Author

Rovedatti, L., primary, Di Sabatino, A., additional, Vidali, F., additional, Fina, D., additional, Biancheri, P., additional, Ubezio, C., additional, Pasini, A., additional, Sampietro, G., additional, Alvisi, C., additional, Perego, M., additional, Foschi, D., additional, MacDonald, T., additional, Monteleone, G., additional, and Corazza, G., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results